This article reviews clinical trial data that assesses the safety, efficacy, and clinical application of spesolimab, an interleukin-36 (IL-36) blocker, for the treatment of generalized pustular psoriasis (GPP).
Data sources:
A review of the literature was conducted using the search terms: “spesolimab,” “BI 655130,” and “spevigo” in MEDLINE (PubMed) and Clinicaltrials.gov from January 1, 1950 to October 31, 2023.
Study selection and data extraction:
Relevant articles in English relating to the pharmacodynamics, pharmacokinetics, efficacy, and safety of spesolimab were included.
Data Synthesis:
In one phase 2 clinical trial evaluating single dose IV spesolimab for GPP flares at day 8, 54% of patients receiving spesolimab had a GPP physician global assessment (GPPGA) pustulation subscore of 0, and 43% had a GPPGA total score of 0 compared with 6% and 11% for the placebo group, respectively. Another phase 2 clinical trial assessing subcutaneous spesolimab found 23% of patients in low-dose, 29% in medium-dose, and 10% of high-dose spesolimab had flares by week 48 compared with 52% of the placebo group. Hazard ratios for time to GPP flare compared with placebo were 0.16 (P = 0.0005), 0.35 (P = 0.0057), and 0.47 (P = 0.027) for the spesolimab groups, respectively. Infection rates were similar across treatment and placebo groups, and severe adverse events such as drug reactions with eosinophilia and systemic symptom (DRESS), cholelithiasis, and breast cancer occurred with spesolimab.
Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:
Spesolimab is a first-in-class IL-36 monoclonal antibody receptor antagonist approved for the treatment of acute GPP flares. It is a safe and effective therapeutic agent in preventing future GPP flares, with no current comparator trials with other GPP agents.
Conclusion:
Spesolimab is a safe and effective treatment for acute GPP flares in adults. Future clinical trials can establish safety and efficacy compared with other agents.
RomitiRHirayamaAArnoneMMagalhaesRF.Generalized pustular psoriasis (von Zumbusch). An Bras Dermatol. 2022;97(1):63-74. doi:10.1016/j.abd.2021.05.011.
4.
PrinzJCChoonSEGriffithsCEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2023;37(2):256-273. doi:10.1111/jdv.18720.
5.
ChoonSEDe La CruzCWolfP, et al. Health-related quality of life in patients with generalized pustular psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2023;38(2):265Z-280Z. doi:10.1111/jdv.19530.
6.
MoritaATsaiTFYeeEYW, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: results from the randomized, double-blind, placebo-controlled Effisayil 1 study. J Dermatol. 2023;50(2):183-194. doi:10.1111/1346-8138.16609.
7.
ZimmermannTMHofmannPChiuGR.A narrative review of the socioeconomic burden associated with generalised pustular psoriasis. Exp Dermatol. 2023;32(8):1219-1226. doi:10.1111/exd.14841.
8.
BachelezHChoonSEMarrakchiS, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440. doi:10.1056/NEJMoa2111563.
9.
ReisnerDVJohnssonFDKotowskyNBrunetteSValdecantosWEyerichK.Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(suppl 1):65-71. doi:10.1007/s40257-021-00663-y.
10.
MoritaAStroberBBurdenAD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541-1551. doi:10.1016/S0140-6736(23)01378-8.
11.
NavariniAAPrinzJCMoritaA, et al. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study. J Eur Acad Dermatol Venereol. 2023;37(4):730-736. doi:10.1111/jdv.18820.
12.
KruegerJPuigLThaçiD.Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(suppl 1):51-64. doi:10.1007/s40257-021-00658-9.
13.
BlairHA.Spesolimab: first approval. Drugs. 2022;82(17):1681-1686. doi:10.1007/s40265-022-01801-4.
14.
BachelezHBarkerJBurdenADNavariniAAKruegerJG.Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033-1047. doi:10.1080/1744666X.2022.2116003.
15.
HawkesJEVisvanathanSKruegerJG.The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab. Front Immunol. 2023;14:1292941. doi:10.3389/fimmu.2023.1292941.
16.
SachenKLArnold GrevingCNTowneJE. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine. 2022;156:155897. doi:10.1016/j.cyto.2022.155897.
17.
BaumPVisvanathanSGarcetS, et al. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149(4):1402-1412. doi:10.1016/j.jaci.2021.09.035.
18.
MarrakchiSPuigL.Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(suppl 1):13-19. doi:10.1007/s40257-021-00655-y.
JosephDThomaCHaeufelTLiX.Assessment of the pharmacokinetics and safety of spesolimab, a humanised anti-interleukin-36 receptor monoclonal antibody, in healthy non-Japanese and Japanese subjects: results from phase I clinical studies. Clin Pharmacokinet. 2022;61(12):1771-1787. doi:10.1007/s40262-022-01176-5.
ZhengMJullienDEyerichK.The prevalence and disease characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(suppl 1):5-12. doi:10.1007/s40257-021-00664-x.
23.
MaçãesCOLéAMTorresT.Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors. J Dermatolog Treat. 2022;33(7):2911-2918. doi:10.1080/09546634.2022.2089335.
DuYYanQChenMDongZWangF.Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review. J Dermatolog Treat. 2022;33(6):2862-2868. doi:10.1080/09546634.2022.2089327.
26.
ChenPLiCXueR, et al. Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. J Dermatolog Treat. 2018;29(4):353-363. doi:10.1080/09546634.2017.1395798.
27.
Czarnecka-OperaczMSadowska-PrzytockaA.The possibilities and principles of methotrexate treatment of psoriasis: the updated knowledge. Postepy Dermatol Alergol. 2014;31(6):392-400. doi:10.5114/pdia.2014.47121.
28.
LuJWangYLiYGongYDingYShiY.Comparative study on the clinical efficacy and safety of acitretin and MTX in the treatment of pustular psoriasis by TLR7/MyD88/CXCL16 pathway. Appl Bionics Biomech. 2022;2022:9640326. doi:10.1155/2022/9640326.
29.
KawakamiHMaedaTAbeN, et al. Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development. J Dermatol. 2015;42(1):94-95. doi:10.1111/1346-8138.12704.
30.
KodaliNBlanchardIKunamneniSLebwohlMG.Current management of generalized pustular psoriasis. Exp Dermatol. 2023;32(8):1204-1218. doi:10.1111/exd.14765.
31.
HausteinUFRytterM.Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14(5):382-388. doi:10.1046/j.1468-3083.2000.00058.x.
32.
ChoonSELaiNMMohammadNANanuNMTeyKEChewSF.Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676-684. doi:10.1111/ijd.12070.
33.
NiinomiIOyamaSInadaA, et al. Current status of adverse event profile of cyclosporine in kidney, stem cell, and heart transplantations using the Japanese pharmacovigilance database. Cureus. 2022;14(9):e29383. doi:10.7759/cureus.29383.
34.
GeorgakopoulosJRIghaniAYeungJ.Short and long-term management of an acute pustular psoriasis flare: a case report. J Cutan Med Surg. 2017;21(5):452-456. doi:10.1177/1203475417712499.
35.
BenjegerdesKEHydeKKivelevitchDMansouriB.Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-144. doi:10.2147/PTT.S98954.
36.
RobinsonAVan VoorheesASHsuS, et al. Treatment of pustular psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2012;67(2):279-288. doi:10.1016/j.jaad.2011.01.032.
37.
FujitaHTeruiTHayamaK, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235-1270. doi:10.1111/1346-8138.14523.
38.
ElewskiBELebwohlMGAnadkatMJ, et al. Rapid and sustained improvements in generalized pustular psoriasis physician global assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. J Am Acad Dermatol. 2023;89(1):36-44. doi:10.1016/j.jaad.2023.02.040.
39.
BurdenADOkuboYZhengM, et al. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study. Exp Dermatol. 2023;32(8):1279-1283. doi:10.1111/exd.14824.
40.
WarrenRBReichAKaszubaA, et al. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023;189(2):161-169. doi:10.1093/bjd/ljad083.
